Martin Brenner, DVM, Ph.D.

Dr. Brenner, iBio’s Chief Scientific Officer, has a strong track record of success heading drug discovery and development teams at several of the world’s leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., where he established and advanced a pipeline of biologics programs in oncology and metabolic diseases. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery by integrating technological innovations across biology, chemistry, automation, machine learning and engineering.